Regenxbio Inc. (RGNX) Reaches New 1-Year Low at $7.23
Regenxbio Inc. (NASDAQ:RGNX) shares reached a new 52-week low during trading on Tuesday . The stock traded as low as $7.23 and last traded at $7.35, with a volume of 261,856 shares. The stock had previously closed at $7.67.
Several research firms have recently commented on RGNX. Zacks Investment Research upgraded Regenxbio from a “sell” rating to a “hold” rating in a report on Wednesday, May 11th. Morgan Stanley lifted their price target on Regenxbio from $34.00 to $36.00 in a report on Friday, April 8th. Chardan Capital reiterated a “buy” rating on shares of Regenxbio in a report on Tuesday, May 10th. Finally, Piper Jaffray Cos. restated a “buy” rating and issued a $33.00 price objective on shares of Regenxbio in a report on Tuesday, July 5th. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the company. The company currently has an average rating of “Buy” and an average price target of $28.35.
The stock’s 50 day moving average is $9.74 and its 200 day moving average is $11.60. The company’s market cap is $192.79 million.
Regenxbio (NASDAQ:RGNX) last released its quarterly earnings data on Thursday, May 5th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.40) by $0.01. Equities research analysts predict that Regenxbio Inc. will post ($2.37) earnings per share for the current year.
In other Regenxbio news, insider Fmr Llc sold 18,300 shares of the company’s stock in a transaction on Tuesday, May 17th. The stock was sold at an average price of $12.41, for a total value of $227,103.00. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.
REGENXBIO Inc is a biotechnology company. The Company is focused on the development, commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy. Its AAV gene delivery platform (its NAV Technology Platform) consists of rights to over 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10 (NAV Vectors).
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.